||A synthetic phospho-peptide corresponding to residues surrounding Tyr207 of human phospho CrkL
||Predicted to work with mouse, rat, and other homologues.
||1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA
||WB, Flow Cytometry
||1.0 - 0.1 µg/ml. Optimum concentration should be determined by the user.
CrkL (CRK Like Proto-Oncogene, Adaptor Protein), which is a V-crk avian sarcoma virus CT10 oncogene homolog-like adapted protein of CRK family, belongs to a novel class of regulatory proteins which include v-Crk and its cellular homologs Crk I and Crk II. Protein structure of CrkL contains several SH2 and SH3 domains. Phospho CrkL plays a central role in cell proliferation, cell adhesion, migration and phagocytic and endocytic pathways (1). Dysfunction of CRKL plays key roles in a variety of human diseases including human malignancies, e.g. chronic myelogenous leukemia, colon cancer and prostate cancer (2-5). Phospho CrkL is known to regulate signaling through interactions of its SH3 domain with proline-rich motif containing proteins, such as SOS, C3G, and p85. In CrkL-induced cell transformation, CrkL association with these proteins and activates SOS1-RAS-RAF-ERK and Src-C3G-RAP1 signaling pathways. The SH2 and SH3 domains associate with effector proteins containing phosphorylated tyrosine (pTyr)-Xaa-Xaa-Pro and Pro-Xaa-Xaa-Pro motifs respectively. The SH3 domains are separated by a linker containing Tyr207 which is phosphorylated by Abl tyrosine kinase.
1. Wang J, et al. (2013) Chemico-biological interactions. 206: 230–8.
2. Ungewiss C, et al. (2016) Scientific reports. 6:18652.
3. Birge RB, et al. (2009) Cell communication and Signaling: CCS. 7:13. 3
4. Panigrahi S, et al. (2012) PLOS ONE. 7:e28395,
5. Singer CF, et al. (2006) Oncol. Rep. 15: 353-9.
This product was added to our catalog on Tuesday 25 October, 2016.